1
Yingya ZHOU
Shi Yixiang, Cai Ningsheng, Li Wenying, Zhou Yingya: Solar thermal generating system based on boundary layer turbine. Tsinghua University, zhang wenbao, September 21, 2011: CN201110140100

The invention relates to the technical field of solar thermal generating systems and discloses a solar thermal generating system based on a boundary layer turbine as well as provides a practical application of the boundary level turbine. The system can use Rankine cycle and organic Rankine cycle to ...


2
Mcphee Fiona, Campbell Jeffrey Allen, Li Wenying, D Andrea Stanley, Zheng Zhizhen Barbara, Good Andrew Charles, Carini David J, Johnson Barry L, Scola Paul Michael: Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus. Bristol Myers Squibb Company, Mcphee Fiona, Campbell Jeffrey Allen, Li Wenying, D Andrea Stanley, Zheng Zhizhen Barbara, Good Andrew Charles, Carini David J, Johnson Barry L, Scola Paul Michael, VOLLES Warren K, November 4, 2004: WO/2004/094452 (132 worldwide citation)

Macrocyclic isoquinoline are disclosed having the general formula: A compound of formula 1: wherein R1 to R9, Q and W are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


3
Vaccaro Wayne, Yang Bingwei Vera, Kim Soong Hoon, Huynh Tram, Tortolani David R, Leavitt Kenneth J, Li Wenying, Doweyko Arthur M, Chen Xiao Tao, Doweyko Lidia: Modulators of the glucocorticoid receptor and method. Bristol Myers Squibb Company, Vaccaro Wayne, Yang Bingwei Vera, Kim Soong Hoon, Huynh Tram, Tortolani David R, Leavitt Kenneth J, Li Wenying, Doweyko Arthur M, Chen Xiao Tao, Doweyko Lidia, sDAVIS Stephen, January 29, 2004: WO/2004/009017 (21 worldwide citation)

Novel non-steroidal compounds are provided which are glucocorticoid receptor modulators which are useful in treating diseases requiring glucocorticoid receptor agonist or antagonist therapy such as obesity, diabetes, inflammatory and immune disorders, and have the structure formula (I), where Z is C ...


4
Regueiro Ren Alicia, Swidorski Jacob, Liu Zheng, Wang Tao, Zhang Zhongxing, Hamann Lawrence G, Meanwell Nicholas A, Carini David J, Li Wenying: Diketopiperidine derivatives as hiv attachment inhibitors. Bristol Myers Squibb Company, Regueiro Ren Alicia, Swidorski Jacob, Liu Zheng, Wang Tao, Zhang Zhongxing, Hamann Lawrence G, Meanwell Nicholas A, Carini David J, Li Wenying, Levis John F, December 30, 2009: WO/2009/158396 (4 worldwide citation)

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketopiperidine derivatives that possess unique antiviral activity are provided. These compounds are useful for the treatment of HIV and AIDS.


5
Arora Vinod Kumar, Christopher Lisa Joy, Cui Donghui, Li Wenying: N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites. Bristol Myers Squibb Company, Arora Vinod Kumar, Christopher Lisa Joy, Cui Donghui, Li Wenying, VANATTEN Mary K, September 21, 2006: WO/2006/099474 (1 worldwide citation)

The present invention is directed to metabolites of 'N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarbo xamide, the compound of formula (I), pharmaceutical compositions thereof, and to methods of using the metabolites and the pharmaceut ...


6
Salvati Mark E, Balog James Aaron, Pickering Dacia A, Giese Soren, Fura Aberra, Li Wenying, Patel Ramesh N, Hanson Ronald L, Mitt Toomas, Roberge Jacques, Corte James R, Spergel Steven H, Rampulla Richard A, Misra Raj, Xiao Hai Yun: Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function. Bristols Myers Squibb Company, September 22, 2004: EP1458723-A1

Fused cyclic compounds method of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.


7
Steele Christopher L, Chen Yijun, Dougherty Brian A, Hofstead Sandra, Lam Kin S, Li Wenying, Xing Zizhuo: Compositions and methods for altering biosynthesis of taxanes and taxane-related compounds. Squibb Bristol Myers Co, February 22, 2006: EP1627068-A2

Isolated nucleic acid and amino acid sequences for phenylalanine aminomutase enzyme and methods for purifying this enzyme are provided. Methods for altering biosynthesis of compounds in plant cell cultures are also provided. In particular, methods for altering production of taxanes and taxane-relate ...


8
Mcphee Fiona, Campbell Jeffrey Allen, Li Wenying, D Andrea Stanley, Zheng Zhizhen Barbara, Good Andrew Charles, Carini David J, Johnson Barry L, Scola Paul Michael, Boy Kenneth M: Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus. Squibb Bristol Myers Co, March 1, 2006: EP1629000-A2

Macrocyclic isoquinoline are disclosed having the general formula: A compound of formula 1: wherein R1 to R9, Q and W are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


9
Mcphee Fiona, Campbell Jeffrey Allen, Li Wenying, D Andrea Stanley, Zheng Zhizhen Barbara, Good Andrew Charles, Carini David J, Johnson Barry L, Scola Paul Michael, Boy Kenneth M: Process for resolving a mixture of alkyl ester enantiomers using an enzyme. Squibb Bristol Myers Co, March 11, 2009: EP2033654-A1

A process for resolving a mixture of alkyl ester enantiomers comprising contacting the mixture with an enzyme effective to preferentially promote the hydrolysis of one of the enatiomers characterized in that the contacting is conducted in the presence of a buffer.


10
Salvati Mark E, Balog James Aaron, Pickering Dacia A, Giese Soren, Fura Aberra, Li Wenying, Patel Ramesh N, Hanson Ronald L, Mitt Toomas, Roberge Jacques, Corte James R, Spergel Steven H, Rampulla Richard A, Misra Raj, Xiao Hai Yun: Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function. Squibb Bristol Myers Co, November 14, 2007: EP1854798-A2

Fused cyclic compounds, method of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.



Click the thumbnails below to visualize the patent trend.